Diagnostic agents for evaluating neurodegenerative processes of human brain.
Project goals
The aim of this project is to develop a non-invasive and effective method of imaging spatial patterns of neurodegeneration using radionuklid labelled monoclonal antibody against beta-III tubulin. The construction of ELISA kit for the detection of neuronspecific tubulin and autoantibodies against beta-III tubulin
Keywords
Public support
Provider
Ministry of Education, Youth and Sports
Programme
EUREKA - European co-operation in the sphere of applied and industrial research and development aimed at the support of multinational co-operation among industrial undertakings, research institutes and universities
Call for proposals
EUREKA 1 (SMSM200132005)
Main participants
VIDIA spol. s r.o.
Contest type
VS - Public tender
Contract ID
—
Alternative language
Project name in Czech
Diagnostické agents pro stanovování neurodegenerativních procesů v lidském mozku.
Annotation in Czech
Vývoj nových ELISA kitů na detekci neurodegenerativních onemocnění v séru a cerebrospinálním moku. Vývoj metodik značení monoklonální protilátky pomocí radionuklidů. Ověření možností využití radionuklidy značených protilátek pro aplikaci in vivo na zvířecích modelech. Experimentální sledování osudu značené protilátky v organismu, v mozku a na řezech mozku. Výroba ELISA souprav, preklinické testování in vivo diagnostika.
Scientific branches
R&D category
—
CEP classification - main branch
FP - Other medical fields
CEP - secondary branch
EC - Immunology
CEP - another secondary branch
EI - Biotechnology and bionics
20801 - Environmental biotechnology
20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
20803 - Environmental biotechnology related ethics
20901 - Industrial biotechnology
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
30102 - Immunology
30106 - Anatomy and morphology (plant science to be 1.6)
30107 - Medicinal chemistry
30108 - Toxicology
30109 - Pathology
30221 - Critical care medicine and Emergency medicine
30223 - Anaesthesiology
30224 - Radiology, nuclear medicine and medical imaging
30225 - Allergy
30226 - Rheumatology
30227 - Geriatrics and gerontology
30229 - Integrative and complementary medicine (alternative practice systems)
30230 - Other clinical medicine subjects
30307 - Nursing
30308 - Nutrition, Dietetics
30309 - Tropical medicine
30310 - Parasitology
30311 - Medical ethics
30312 - Substance abuse
30401 - Health-related biotechnology
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
30404 - Biomaterials (as related to medical implants, devices, sensors)
30405 - Medical biotechnology related ethics
30501 - Forensic science
30502 - Other medical science
40401 - Agricultural biotechnology and food biotechnology
40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
Byly splněny cíle projektu ve stanoveném rozsahu podle zadání
Solution timeline
Realization period - beginning
Jan 1, 2001
Realization period - end
Jan 1, 2003
Project status
U - Finished project
Latest support payment
—
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP/2004/MSM/MSM4OE/U/N/4:1
Data delivery date
Sep 21, 2004
Finance
Total approved costs
9,605 thou. CZK
Public financial support
4,205 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
5,400 thou. CZK
Recognised costs
9 605 CZK thou.
Public support
4 205 CZK thou.
0%
Provider
Ministry of Education, Youth and Sports
CEP
FP - Other medical fields
Solution period
01. 01. 2001 - 01. 01. 2003